[1]
|
Rich, M.W. (2006) Epidemiology, Clinical Features, and Prognosis of Acute Myocardial Infarction in the Elderly. The American Journal of Geriatric Cardiology, 15, 7-13. https://doi.org/10.1111/j.1076-7460.2006.05273.x
|
[2]
|
van Peet, P.G., Drewes, Y.M., de Craen, A.J., Gussekloo, J. and de Ruijter, W. (2013) NT-proBNP Best Predictor of Car-diovascular Events and Cardiovascular Mortality in Secondary Prevention in Very Old Age: The Leiden 85-Plus Study. PLOS ONE, 8, e81400. https://doi.org/10.1371/journal.pone.0081400
|
[3]
|
Zhang, M., Liu, H.H., Jin, J.L., et al. (2020) Lipoprotein (a) and Cardiovascular Death in Oldest-Old (≥ 80 Years) Patients with Acute Myocardial Infarction: A Prospective Cohort Study. Atherosclerosis, 312, 54-59.
https://doi.org/10.1016/j.atherosclerosis.2020.08.033
|
[4]
|
Tsimikas, S., Fazio, S., Ferdinand, K.C., et al. (2018) NHLBI Working Group Recommendations to Reduce Lipoprotein (a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the American College of Cardiology, 71, 177-192. https://doi.org/10.1016/j.jacc.2017.11.014
|
[5]
|
Berg, K. (1963) A New Serum Type System in Man—The Lp Sys-tem. Acta Pathologica Microbiologica Scandinavica, 59, 369-382. https://doi.org/10.1111/j.1699-0463.1963.tb01808.x
|
[6]
|
Catapano, A.L., Graham, I., De Backer, G., et al. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidae-mias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the Special Contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Athero-sclerosis, 253, 281-344.
|
[7]
|
Gencer, B., Kronenberg, F., Stroes, E.S. and Mach, F. (2017) Lipoprotein (a): The Reve-nant. European Heart Journal, 38, 1553-1560. https://doi.org/10.1093/eurheartj/ehx033
|
[8]
|
Schmidt, K., Noureen, A., Kronenberg, F. and Utermann, G. (2016) Structure, Function, and Genetics of Lipoprotein (a). Journal of Lipid Re-search, 57, 1339-1359. https://doi.org/10.1194/jlr.R067314
|
[9]
|
Nordestgaard, B.G. and Langsted, A. (2016) Lipoprotein (a) as a Cause of Cardiovascular Disease: Insights from Epidemiology, Genetics, and Biology. Journal of Li-pid Research, 57, 1953-1975. https://doi.org/10.1194/jlr.R071233
|
[10]
|
Cesaro, A., Schiavo, A., Moscarella, E., et al. (2021) Lipoprotein (a): A Genetic Marker for Cardiovascular Disease and Target for Emerging Therapies. Journal of Cardiovascular Medicine, 22, 151-161.
https://doi.org/10.2459/JCM.0000000000001077
|
[11]
|
Vavuranakis, M.A., Jones, S.R., Ziogos, E., et al. (2022) The Trajectory of Lipoprotein (a) during the Peri- and Early Postinfarction Period and the Impact of Proprotein Convert-ase Subtilisin/Kexin Type 9 Inhibition. The American Journal of Cardiology, 171, 1-6. https://doi.org/10.1016/j.amjcard.2022.01.058
|
[12]
|
Mitsuda, T., Uemura, Y., Ishii, H., et al. (2016) Lipoprotein (a) Levels Predict Adverse Vascular Events after Acute Myocardial Infarction. Heart and Vessels, 31, 1923-1929. https://doi.org/10.1007/s00380-016-0823-0
|
[13]
|
Rashid, S., Khurshid, R., Amir, U.F., et al. (2017) A Novel Link between Adipokines and Lipoprotein (A) to Contemplate Their Diagnostic Role in Patients with Stemi and Nstemi. Journal of Ayub Medical College Abbottabad, 29, 112-117.
|
[14]
|
Galasso, G., De Angelis, E., Silverio, A., et al. (2021) Predictors of Recurrent Ischemic Events in Patients with ST- Segment Elevation Myocardial Infarction. The American Journal of Cardiology, 159, 44-51.
https://doi.org/10.1016/j.amjcard.2021.08.019
|
[15]
|
Kronenberg, F., Mora, S., Stroes, E., et al. (2022) Lipoprotein (a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement. European Heart Journal, 43, 3925-3946.
https://doi.org/10.1093/eurheartj/ehac361
|
[16]
|
Ruscica, M., Sirtori, C.R., Corsini, A., et al. (2021) Lipoprotein (a): Knowns, Unknowns and Uncertainties. Pharmacological Research, 173, Article ID: 105812. https://doi.org/10.1016/j.phrs.2021.105812
|
[17]
|
Bdeir, K., Cane, W., Canziani, G., et al. (1999) Defensin Promotes the Binding of Lipoprotein (a) to Vascular Matrix. Blood, 94, 2007-2019.
|
[18]
|
Kreuzer, J., Lloyd, M.B., Bok, D., et al. (1994) Lipoprotein (a) Displays Increased Accumulation Compared with Low- Density Lipoprotein in the Murine Arteri-al Wall. Chemistry and Physics of Lipids, 67-68, 175-190.
https://doi.org/10.1016/0009-3084(94)90137-6
|
[19]
|
Oikonomou, E., Souvaliotis, N., Lampsas, S., et al. (2022) Endothelial Dysfunction in Acute and Long Standing COVID-19: A Prospective Cohort Study. Vascular Pharmacology, 144, Article ID: 106975.
https://doi.org/10.1016/j.vph.2022.106975
|
[20]
|
Sotiriou, S.N., Orlova, V.V., Al-Fakhri, N., et al. (2006) Lipopro-tein (a) in Atherosclerotic Plaques Recruits Inflammatory Cells through Interaction with Mac-1 Integrin. The FASEB Journal, 20, 559-561.
https://doi.org/10.1096/fj.05-4857fje
|
[21]
|
Klezovitch, O., Edelstein, C. and Scanu, A.M. (2001) Stimulation of In-terleukin-8 Production in Human THP-1 Macrophages by Apolipoprotein (a). Evidence for a Critical Involvement of Elements in Its C-Terminal Domain. Journal of Biological Chemistry, 276, 46864-46869. https://doi.org/10.1074/jbc.M107943200
|
[22]
|
Labudovic, D., Kostovska, I., Tosheska, T.K., et al. (2019) Lipopro-tein (a)—Link between Atherogenesis and Thrombosis. Prague Medical Report, 120, 39-51. https://doi.org/10.14712/23362936.2019.9
|
[23]
|
Grainger, D.J., Kemp, P.R., Liu, A.C., Lawn, R.M. and Metcalfe, J.C. (1994) Activation of Transforming Growth Factor-β Is Inhibited in Transgenic Apolipoprotein(a) Mice. Nature, 370, 460-462. https://doi.org/10.1038/370460a0
|
[24]
|
Badimon, L., Padro, T., Arderiu, G., et al. (2022) Extracellular Vesicles in Atherothrombosis: From Biomarkers and Precision Medicine to Therapeutic Targets. Immunological Reviews, 312, 6-19. https://doi.org/10.1111/imr.13127
|
[25]
|
Wang, C., Liu, C., Shi, J., et al. (2023) Nicotine Exacerbates Endothelial Dysfunction and Drives Atherosclerosis via Extracellular Vesicle-miRNA. Cardiovascular Research, 119, 729-742. https://doi.org/10.1093/cvr/cvac140
|
[26]
|
Klezovitch, O., Edelstein, C., Zhu, L.Y. and Scanu, A.M. (1998) Apolipoprotein (a) Binds via Its C-Terminal Domain to the Protein Core of the Proteoglycan Decorin. Implications for the Retention of Lipoprotein (a) in Atherosclerotic Lesions. Journal of Biological Chemistry, 273, 23856-23865. https://doi.org/10.1074/jbc.273.37.23856
|
[27]
|
Ganne, F., Vasse, M., Beaudeux, J.L., et al. (1999) Increased Ex-pression of u-PA and u-PAR on Monocytes by LDL and Lp(a) Lipoproteins—Consequences for Plasmin Generation and Monocyte Adhesion. Thrombosis and Haemostasis, 81, 594-600. https://doi.org/10.1055/s-0037-1614531
|
[28]
|
Sankhesara, D.M., Lan, N., Gilfillan, P., et al. (2023) Lipoprotein (a) Is Associated with Thrombus Burden in Culprit Arteries of Younger Patients with ST-Segment Elevation Myocardial In-farction. Cardiology, 148, 98-102.
https://doi.org/10.1159/000529600
|
[29]
|
Neeland, I.J., Patel, R.S., Eshtehardi, P., et al. (2012) Coronary Angio-graphic Scoring Systems: An Evaluation of Their Equivalence and Validity. American Heart Journal, 164, 547-552. https://doi.org/10.1016/j.ahj.2012.07.007
|
[30]
|
Xue, Y., Jian, S., Zhou, W., et al. (2021) Associations of Lipopro-tein(a) with Coronary Atherosclerotic Burden and All-Cause Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 8, Article 638679.
https://doi.org/10.3389/fcvm.2021.638679
|
[31]
|
Ferretti, G., Bacchetti, T., Johnston, T.P., et al. (2018) Lipoprotein (a): A Missing Culprit in the Management of Athero-Thrombosis? Journal of Cellular Physiology, 233, 2966-2981. https://doi.org/10.1002/jcp.26050
|
[32]
|
Caplice, N.M., Panetta, C., Peterson, T.E., et al. (2001) Lipoprotein (a) Binds and Inactivates Tissue Factor Pathway Inhibitor: A Novel Link between Lipoproteins and Thrombosis. Blood, 98, 2980-2987.
https://doi.org/10.1182/blood.V98.10.2980
|
[33]
|
Scanu, A.M. (2003) Lipoprotein (a) and the Atherothrombotic Process: Mechanistic Insights and Clinical Implications. Current Atherosclerosis Reports, 5, 106-113. https://doi.org/10.1007/s11883-003-0081-3
|
[34]
|
Boffa, M.B. and Koschinsky, M.L. (2016) Lipoprotein (a): Truly a Direct Prothrombotic Factor in Cardiovascular Disease? Journal of Lipid Research, 57, 745-757. https://doi.org/10.1194/jlr.R060582
|
[35]
|
Ezratty, A., Simon, D.I. and Loscalzo, J. (1993) Lipoprotein (a) Binds to Human Platelets and Attenuates Plasminogen Binding and Activation. Biochemistry, 32, 4628-4633. https://doi.org/10.1021/bi00068a021
|
[36]
|
van der Valk, F.M., Bekkering, S., Kroon, J., et al. (2016) Oxidized Phospholipids on Lipoprotein (a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 134, 611-624.
https://doi.org/10.1161/CIRCULATIONAHA.116.020838
|
[37]
|
Lee, S., Birukov, K.G., Romanoski, C.E., et al. (2012) Role of Phospholipid Oxidation Products in Atherosclerosis. Circulation Research, 111, 778-799. https://doi.org/10.1161/CIRCRESAHA.111.256859
|
[38]
|
Wang, Y., Zhao, X., Zhou, P., et al. (2021) Impact of Postprocedural High-Sensitivity C-Reactive Protein on Lipoprotein (a)-Associated Cardiovascular Risk with ST-Segment Elevation Myocardial Infarction with Percutaneous Coronary Intervention. The American Journal of Cardiology, 150, 8-14. https://doi.org/10.1016/j.amjcard.2021.03.038
|
[39]
|
Ray, K.K., Stoekenbroek, R.M., Kallend, D., et al. (2018) Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Circulation, 138, 1304-1316.
https://doi.org/10.1161/CIRCULATIONAHA.118.034710
|
[40]
|
Dyrbus, K., Gasior, M., Penson, P., Ray, K.K. and Banach, M. (2020) Inclisiran-New Hope in the Management of Lipid Disorders? Journal of Clinical Lipidology, 14, 16-27. https://doi.org/10.1016/j.jacl.2019.11.001
|
[41]
|
Raal, F.J., Giugliano, R.P., Sabatine, M.S., et al. (2016) PCSK9 Inhibition-Mediated Reduction in Lp (a) with Evolocumab: An Analysis of 10 Clinical Trials and the LDL Re-ceptor’s Role. Journal of Lipid Research, 57, 1086-1096.
https://doi.org/10.1194/jlr.P065334
|
[42]
|
Enas, E.A., Varkey, B., Dharmarajan, T.S., Pare, G. and Bahl, V.K. (2019) Lipoprotein (a): An Independent, Genetic, and Causal Factor for Cardiovascular Disease and Acute Myocardial Infarction. Indian Heart Journal, 71, 99-112.
https://doi.org/10.1016/j.ihj.2019.03.004
|
[43]
|
Tsimikas, S., Viney, N.J., Hughes, S.G., et al. (2015) Antisense Therapy Targeting Apolipoprotein (a): A Randomised, Double-Blind, Placebo-Controlled Phase 1 Study. The Lancet, 386, 1472-1483.
https://doi.org/10.1016/S0140-6736(15)61252-1
|
[44]
|
Xue, Y., Shen, J., Hong, W., et al. (2021) Risk Stratification of ST-Segment Elevation Myocardial Infarction (STEMI) Patients Using Machine Learning Based on Lipid Profiles. Li-pids in Health and Disease, 20, Article No. 48.
https://doi.org/10.1186/s12944-021-01475-z
|